Country Trust Bank cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 172,340 shares of the company’s stock after selling 9,604 shares during the period. Country Trust Bank’s holdings in Johnson & Johnson were worth $25,658,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. APG Asset Management N.V. increased its position in shares of Johnson & Johnson by 3.8% during the first quarter. APG Asset Management N.V. now owns 4,181,079 shares of the company’s stock valued at $548,265,000 after acquiring an additional 152,597 shares during the last quarter. Morgan Stanley increased its position in shares of Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock valued at $2,727,694,000 after acquiring an additional 54,563 shares during the last quarter. Tudor Investment Corp Et Al acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $239,000. Tower Research Capital LLC TRC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $429,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $3,485,000. Institutional investors and hedge funds own 67.44% of the company’s stock.
A number of equities research analysts have weighed in on JNJ shares. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Raymond James lifted their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $161.00 to $164.00 in a report on Monday, July 20th. Finally, Cantor Fitzgerald lifted their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $164.93.
NYSE JNJ opened at $148.10 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The stock has a market capitalization of $389.92 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The firm has a 50 day moving average of $148.57 and a two-hundred day moving average of $146.59.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. During the same quarter in the previous year, the business posted $2.12 EPS. The firm’s revenue was up 1.7% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 8 earnings per share for the current fiscal year.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: Municipal Bonds
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.